Trends in the indications and survival in pediatric heart transplants: A 24-year single-center experience in 307 patients

Rochus K. Voeller, Deirdre J. Epstein, Tracey J. Guthrie, Sanjiv K. Gandhi, Charles E. Canter, Charles B. Huddleston

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

Heart transplantation is the only viable treatment for children with end-stage heart failure due to congenital heart disease (CHD) or cardiomyopathy. This study reviewed the trends in the indications for transplant and survival after transplant during the past 24 years. A retrospective review was performed of the 307 heart transplants performed at our center since 1986. To analyze the trends in the indications for transplant as well as operative death and late-survival, the data were divided into three periods in 8-year increments: 1986 to 1993 (50 patients), 1994 to 2001 (116 patients), and 2002 to 2009 (141 patients). The indications for transplantation were 39% cardiomyopathy, 57% CHD, and 4% retransplant. Of the 173 with CHD, 139 (80%) had single-ventricle (SV) anomalies. In the CHD group, transplantation for failed SV palliation, including Fontan procedure, became the predominant indication in the last 8-year interval of our program. Survival after transplant was the best in patients with cardiomyopathy and the worst in patients with failed palliations for SV anomalies, including failed Fontan procedures. Transplantation for heart failure related to failed SV palliation has become the most common indication for patients with CHD. The high-risk nature of these transplants will have significant implications for heart transplant programs as more infants with SV anomalies survive palliative procedures performed during infancy.

Original languageEnglish
Pages (from-to)807-816
Number of pages10
JournalAnnals of Thoracic Surgery
Volume94
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Dive into the research topics of 'Trends in the indications and survival in pediatric heart transplants: A 24-year single-center experience in 307 patients'. Together they form a unique fingerprint.

Cite this